Back to dashboard
CommercialCoverageMedium impact

Drug Alert – Concurrent Use of GLP-1 and DPP-4

EmblemHealth·Endocrinology, Family Medicine, Internal Medicine +1 more·Pharmacy
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply
—

Summary

EmblemHealth and ConnectiCare no longer support concurrent use of GLP-1 and DPP-4 inhibitor medications for diabetes patients due to lack of clinical benefit. Providers should review patients on both drug classes and eliminate one to simplify medication regimens per ADA and AACE guidelines.

Action Required

Action needed
Immediately: Providers should review all diabetes patients currently prescribed both GLP-1 agonists and DPP-4 inhibitors. Clinical staff must identify patients on both medication classes using the drug lists provided in the full policy announcements and work with prescribing physicians to discontinue one medication. Update medication reconciliation protocols to flag concurrent use of these drug classes.

Related policy hubs